Krystal Biotech, Inc.

NASDAQ:KRYS

Biotechnology

Healthcare
$315.34 +5.66%

+$18.29 today

Market cap
$9.34B
Beta
0.53
P/E (TTM)
44.5
EPS (TTM)
$7.68
52W Low $130.17High $347.67

Volume 0.35M

Average 0.29M

KRYS Interest Income

Income earned on cash, deposits, and investments held by the company.

Krystal Biotech, Inc.NASDAQ: KRYS

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income growth accelerates

Q2 FY2026 interest income of $7.66M rose 2.6% year over year, ahead of the -73.0% change in trailing-twelve-month interest income. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at +75.4% a year.

Context

  • Interest income amounted to 7.2% of revenue in FY2025, down 3.0 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.6% holds above the trailing-twelve-month pace of -73.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$7.66M-1.2% QoQ
Last fiscal yearDec 2025
$28.18M-5.0% YoY
LTMJun 2026
$7.95M-73.0% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.6%——
1 year-5.0%——
3-year CAGR+75.4%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
28.18M USD
Year-over-year change
-5.0%
4-year CAGR
+245.8%

Interest Income vs competitors

How KRYS compares with its peers on the latest reported figures

  • KRYS's LTM Jun 2026 interest income of $7.95M is the 2nd highest of the 6 companies compared; the peer median is $3.45M.
  • Its year-over-year change of -73.0% is the 4th highest of 6, against a peer median of -9.0%.
  • Interest income amounts to 1.8% of revenue for KRYS, versus a peer median of 3.9%.
KRYS Competitors Peer median
Interest Income for KRYS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$12.81M -9.0%+39.8%—
KRYSKrystal Biotech, Inc.LTM Jun 2026$7.95M -73.0%+75.4%1.8%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$5.6M +18.8%+134.5%38.5%
RGNXREGENXBIO Inc.LTM Mar 2026$3.45M +2031.5%+229.8%3.9%
MGTXMeiraGTx Holdings plcLTM Mar 2026$1.04M -74.2%+32.8%1.3%
SANASana Biotechnology, Inc.LTM Mar 2026$962K -88.6%+0.8%—
Peer median (excluding KRYS) $3.45M-9.0%+39.8%3.9%

Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0050.7M290.52M389.13M
Cost of Revenue003.09M20.06M28.77M
Gross Profit0047.61M270.45M360.36M
Gross Margin——93.9%93.1%92.6%
Research & Development27.88M42.46M46.43M53.57M58.05M
Selling, General & Admin40.39M77.74M98.4M113.69M146.74M
Operating Expenses68.28M145.2M157.33M204.76M199.06M
Depreciation & Amortization2.77M4.05M5.01M6.71M6.55M
EBITDA(65.31M)(116.14M)(92.22M)109.91M196.02M
EBITDA Margin——-181.9%37.8%50.4%
Operating Income(68.28M)(145.2M)(109.73M)65.7M161.3M
Operating Margin——-216.4%22.6%41.5%
Interest Income197K5.22M22.62M29.66M28.18M
Interest Expense1.49M0000
Other Income / Expenses(1.3M)5.22M122.62M29.66M28.18M
Income Before Tax(69.57M)(139.98M)12.9M95.36M189.47M
Pre-Tax Margin——25.4%32.8%48.7%
Income Tax Expense001.97M6.2M(15.36M)
Net Income(69.57M)(139.98M)10.93M89.16M204.83M
Net Margin——21.6%30.7%52.6%
EPS (Basic)(3.13)(5.49)0.403.127.08
EPS (Diluted)(3.13)(5.49)0.393.006.84
Weighted Avg Shares22.2M25.49M27.15M28.59M28.94M
Weighted Avg Shares (Diluted)22.2M25.49M27.75M29.74M29.95M

Krystal Biotech, Inc.

NASDAQ:KRYS

Intrinsic Alpha fair value

Locked

Current Price

$315.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.